Anew Labs, the AI-pharma company spun out of ByteDance, has closed its first independent financing round: $290 million total, at a post-money valuation of about $1.5 billion, with ByteDance keeping a 56% stake and retaining control. According to 36Kr and Jiemian News, investors include HSG (formerly Sequoia China), IDG Capital, GL Ventures, 5Y Capital, Gaorong Capital and Chunhua Venture Capital, joined by several domestic pharmaceutical industry groups as strategic investors. The round is reported to be the largest single financing in China's
[1][2]AI-pharma sector in 2026.
The story here is structure, not the headline number. Anew Labs began as ByteDance's internal drug-discovery team — AI4S algorithm researchers plus senior pharma experts — was spun out in June, and closed a marquee round within three months. But ByteDance did not let go the way most Big Tech spin-offs do: it kept 56%. This middle form — spin out the business, keep control, invite external capital — is becoming the third answer for how large companies handle non-core AI assets: neither fully incubate nor fully sell.
The second layer is sector cadence. AI pharma is a famously slow business: clinical timelines run in years, failure rates stay high, and valuation narratives depend on milestones. A $1.5 billion valuation and a $290 million round are top-tier in AI pharma and a line item on ByteDance's balance sheet. 36Kr's framing states the logic plainly: from Google (Isomorphic Labs) to ByteDance, every big tech company will eventually own a pharma arm — not because they believe in drugs, but because they hold the compute, data and algorithm talent pharma now needs, and those assets are temporarily idle in the frontier-model race.
The attribution boundaries need stating. The $290 million and $1.5 billion figures come from a Reuters report relayed by 36Kr and Jiemian; neither ByteDance nor Anew Labs has issued official confirmation. The "strategic investors" list is not fully disclosed, and no detailed disclosure covers pipeline stage or team size after the split. The "largest round of the year" framing is 36Kr's and Gelonghui's, based on comparable public deals.
Placed back in this week's context, the news forms a contrast with the Gemini 4 Pro leak and the Step 5 Preview launch: frontier models race on speed, while AI pharma digests the same technology on a decade-scale timeline. ByteDance's 56% says it wants to keep this card; the flood of external capital says the market will pay for the slow track. Both judgments holding at once is the norm for AI capital markets in 2026.
As of writing, Anew Labs has not issued an official announcement about the round. Two verification points are worth tracking: whether the spun-off team can advance its pipeline independently rather than on ByteDance's internal resources, and how many clinical milestones this money will cover. $290 million is a starting point in AI pharma, not an ending.
A final structural point: the round values a company that has been independent for three months at $1.5 billion — a number set by a handful of investors, not discovered by the market. That is normal for AI deals in 2026 and worth saying plainly: the valuation is a negotiation result, not a market price. The durable signal is the investor list — the same names that priced frontier-model companies are now pricing drug-discovery platforms, while ByteDance keeps operational control. That kind of structure does not get assembled by accident.
[1][2]